Acepodia, Inc.

Acepodia, Inc. is a clinical-stage biotechnology company that develops cell therapies using its antibody cell conjugation (ACC) platform technology to address cancer care. Its pipeline includes AD2C, which targets GPC3 for HCC and is in the preclinical stage, and ACE 1831, which targets CD20 and is in a phase 1 clinical trial. The company is based in Grand Cayman, the Cayman Islands.